Milena M.
- Country
- Italy
- Department
- Ematologia
Research Overview
- Randomized, Multicenter, Open-Label Study Comparing Bortezomib-Melphalan-Prednisone With/Without Daratumumab vs. Lenalidomide-Dexamethasone With/Without Daratumumab in ASCT-Ineligible Multiple Myeloma Patients
- Evaluation of Gemtuzumab Ozogamicin with Chemotherapy on Minimal Residual Disease in Adult Patients with Favorable-Intermediate-Risk Acute Myeloid Leukemia
- Evaluation of Revumenib Combined with Azacitidine and Venetoclax in Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML Patients Ineligible for Intensive Chemotherapy
Data & Insights
Has run more than one trial at 26 of 194 partner sites.
Specializations
Hematologic malignancies
Clinical research in acute myeloid leukemia and related high-risk blood cancers, with attention to targeted and immunologic treatment strategies for patients who are not candidates for intensive therapy.
- Acute myeloid leukemia
- Minimal residual disease
- Gemtuzumab ozogamicin
- Multiple myeloma
Work in this area also includes treatment approaches for older or transplant-ineligible patients, with focus on disease control and response assessment.
Breast cancer
Active involvement in early and advanced breast cancer, including triple-negative breast cancer, hormone receptor-positive disease, and HER2-negative subtypes.
- Triple-negative breast cancer
- Advanced breast cancer
- Endocrine therapy
- Antibody-drug conjugates
The therapeutic landscape includes endocrine-based regimens, targeted agents, and perioperative strategies for recurrence prevention and metastatic disease control.
Urothelial and bladder cancer
Research centered on non-muscle-invasive bladder cancer, muscle invasive bladder cancer, and advanced urothelial carcinoma, including patients with recurrent or metastatic disease.
- High-risk non-muscle-invasive bladder cancer
- Metastatic urothelial carcinoma
- Intravesical therapy
- Immune checkpoint inhibition
This area also covers biomarker-informed treatment selection and maintenance approaches after prior systemic therapy.
Renal cell carcinoma
Clinical interest in clear cell renal cell carcinoma and metastatic kidney cancer, with emphasis on immunotherapy-based combinations and perioperative or metastatic treatment strategies.
- Metastatic renal cell carcinoma
- Oligometastatic disease
- Anti-PD-1 therapy
- Targeted therapy
Research also includes management of patients with locally advanced disease and those receiving treatment after immune-based induction.
Other solid tumors and rare conditions
Additional research activity spans non-small-cell lung cancer, prostate cancer, pancreatic ductal adenocarcinoma, and hereditary angioedema.
- EGFR-mutated non-small-cell lung cancer
- Metastatic castration-resistant prostate cancer
- Pancreatic ductal adenocarcinoma
- Hereditary angioedema
These interests reflect participation in studies of targeted therapy, radiotherapy integration, and prophylactic treatment for recurrent angioedema attacks.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.